In addition, owing to gp96 overexpression in brain metastatic cancer cells and its significant roles in the pathophysiological processes of brain metastases, this EC‐K1 LPS‐free outer membrane‐based biomimetic BBB‐penetrating strategy possesses enormous potential for delivering systemic therapy to treat both preclinical and clinical gp96‐overexpressing intracranial malignancies. This evidence concerns the gene HSP90B1 and metastatic malignant neoplasm.